PMID- 34901817
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211215
IS  - 2589-9864 (Electronic)
IS  - 2589-9864 (Linking)
VI  - 16
DP  - 2021
TI  - Overnight switch from levetiracetam to brivaracetam. Safety and tolerability.
PG  - 100504
LID - 10.1016/j.ebr.2021.100504 [doi]
LID - 100504
AB  - Brivaracetam is a newer antiseizure medication than levetiracetam. It has a more 
      selective action on the synaptic vesicle glycoprotein 2A binding site, and it 
      seems to provide a more favorable neuropsychiatric profile. The aim of this study 
      was to assess the safety and tolerability of an overnight switch from 
      levetiracetam to brivaracetam. This was a retrospective descriptive study 
      including patients with epilepsy treated with levetiracetam, who switched due to 
      inefficacy or previous adverse events (AEs). In total, forty-one patients were 
      included (mean age 40.9 +/- 17.8 years, women 48.8%). Focal epilepsy represented 
      75.6% (n = 31) of patients (structural cause [n = 25], unknown cause [n = 6]). 
      Four patients had idiopathic generalized epilepsy, two had developmental and 
      epileptic encephalopathy and four patients were unclassified. The reason to start 
      brivaracetam was inefficacy in 53.7% (n = 22), AEs in 65.9% (25/27 
      neuropsychiatric) and both in 19.5% (n = 8). Brivaracetam-related AEs were 
      reported in 24.4%. Neuropsychological AEs associated with the previous use of 
      levetiracetam improved in 76% of patients. Treatment was discontinued in 19.5% 
      patients. Patients' reported seizure frequency improved, worsened and remained 
      stable in 26.8%, 12.2%, and 61.0% of the cases, respectively. An overnight 
      switching to brivaracetam is safe and well tolerated. This treatment can improve 
      levetiracetam-related neuropsychiatric AEs.
CI  - (c) 2021 The Authors.
FAU - Abraira, L
AU  - Abraira L
AD  - Epilepsy Unit, Neurology Department, Vall d'Hebron University Hospital, Passeig 
      de la Vall d'Hebron, 119, 08035 Barcelona, Spain.
FAU - Salas-Puig, J
AU  - Salas-Puig J
AD  - Epilepsy Unit, Neurology Department, Vall d'Hebron University Hospital, Passeig 
      de la Vall d'Hebron, 119, 08035 Barcelona, Spain.
FAU - Quintana, M
AU  - Quintana M
AD  - Epilepsy Unit, Neurology Department, Vall d'Hebron University Hospital, Passeig 
      de la Vall d'Hebron, 119, 08035 Barcelona, Spain.
FAU - Seijo-Raposo, I M
AU  - Seijo-Raposo IM
AD  - Epilepsy Unit, Neurology Department, Vall d'Hebron University Hospital, Passeig 
      de la Vall d'Hebron, 119, 08035 Barcelona, Spain.
FAU - Santamarina, E
AU  - Santamarina E
AD  - Epilepsy Unit, Neurology Department, Vall d'Hebron University Hospital, Passeig 
      de la Vall d'Hebron, 119, 08035 Barcelona, Spain.
FAU - Fonseca, E
AU  - Fonseca E
AD  - Epilepsy Unit, Neurology Department, Vall d'Hebron University Hospital, Passeig 
      de la Vall d'Hebron, 119, 08035 Barcelona, Spain.
FAU - Toledo, M
AU  - Toledo M
AD  - Epilepsy Unit, Neurology Department, Vall d'Hebron University Hospital, Passeig 
      de la Vall d'Hebron, 119, 08035 Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20211114
PL  - United States
TA  - Epilepsy Behav Rep
JT  - Epilepsy & behavior reports
JID - 101750909
PMC - PMC8640256
OTO - NOTNLM
OT  - Antiseizure medication
OT  - Brivaracetam
OT  - Epilepsy
OT  - Levetiracetam
OT  - Safety profile
OT  - Tolerability
COIS- The authors declare the following financial interests/personal relationships 
      which may be considered as potential competing interests: L. Abraira declares 
      research funding and speaker fees from UCB Pharma, BIAL Pharmaceutical, EISAI 
      Inc, Sanofi Genzyme, GW Pharmaceuticals and Esteve laboratorios. J. Salas-Puig 
      declares funding and honoraria from UCB Pharma, BIAL Pharmaceutical, EISAI Inc. 
      and Esteve laboratorios. M. Quintana has no conflicts of interest to declare. I. 
      M. Seijo-Raposo declares research funding from UCB Pharma, Neuraxpharm, and GW 
      pharmaceuticals. E. Santamarina declares research funding and speaker fees from 
      UCB Pharma, BIAL Pharmaceutical, EISAI Inc, Arvelle, and Esteve laboratorios. E. 
      Fonseca declares research funding and speaker fees from UCB Pharma, Esteve 
      laboratorios, Eisai Inc, GW Pharmaceuticals, BIAL Pharmaceutical and Sanofi 
      Genzyme. M. Toledo declares research funding and speaker fees from UCB Pharma, 
      BIAL Pharmaceutical, EISAI Inc, Sanofi, Arvelle, and Esteve laboratorios.
EDAT- 2021/12/14 06:00
MHDA- 2021/12/14 06:01
PMCR- 2021/11/14
CRDT- 2021/12/13 18:17
PHST- 2021/07/21 00:00 [received]
PHST- 2021/10/26 00:00 [revised]
PHST- 2021/11/09 00:00 [accepted]
PHST- 2021/12/13 18:17 [entrez]
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2021/12/14 06:01 [medline]
PHST- 2021/11/14 00:00 [pmc-release]
AID - S2589-9864(21)00078-2 [pii]
AID - 100504 [pii]
AID - 10.1016/j.ebr.2021.100504 [doi]
PST - epublish
SO  - Epilepsy Behav Rep. 2021 Nov 14;16:100504. doi: 10.1016/j.ebr.2021.100504. 
      eCollection 2021.